Insilico Medicine's AI-Designed GIPR Antagonist ISM0676 Achieves 31.3% Weight Loss in Preclinical Studies
核心洞察
Insilico Medicine (搜索) nominated ISM0676 (搜索), an AI-designed oral GIPR (搜索) antagonist, as a preclinical candidate after just 14 months of development using fewer than 200 synthesized molecules.
The compound demonstrated up to 31.3% body weight loss in diet-induced obese mice when combined with semaglutide, significantly outperforming monotherapy results.
ISM0676 (搜索) showed excellent metabolic stability, low drug-drug interaction risk, and favorable safety profiles, positioning it as a potential breakthrough for obesity treatment.
Insilico Medicine (搜索) has nominated ISM0676 (搜索), an orally bioavailable small molecule antagonist targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR (搜索)), as a preclinical candidate for obesity treatment. The AI-driven drug discovery company achieved this milestone in just 14 months from project initiation, synthesizing and testing fewer than 200 molecules using its proprietary Chemistry42 platform.
Breakthrough Efficacy in Preclinical Studies
In diet-induced obese (DIO) humanized GIPR (搜索) mice, ISM0676 (搜索) demonstrated significant therapeutic potential. As monotherapy, the compound achieved a 10.4% reduction in body weight from baseline after 27 days of dosing, compared to a 3% increase observed in the vehicle control group. The results became even more compelling when ISM0676 was combined with semaglutide, leading to a substantial 31.3% body weight loss.
The treatment also improved body composition, as indicated by a higher lean mass-to-body weight ratio, addressing one of the key limitations of current obesity therapies that often result in lean mass loss.
Addressing Market Demands and Current Limitations
The global obesity treatment market is projected to reach $60.53 billion by 2030, driven by increasing demand for effective therapeutic solutions. Current therapies, including GLP-1 receptor agonists (GLP-1RAs), face significant challenges including lean mass loss, efficacy plateaus, rapid weight regain upon withdrawal, and patient adherence issues.
The GIP receptor plays a crucial role in metabolism by regulating insulin secretion, controlling fat storage in tissues, maintaining bone composition and turnover, and influencing appetite through the central nervous system. By targeting GIPR (搜索) in combination with GLP-1 therapies, ISM0676 (搜索) could potentially overcome key shortcomings of current obesity treatments and deliver more sustainable, patient-friendly solutions for weight management.
Superior Drug Properties and Development Efficiency
ISM0676 (搜索) demonstrated excellent in vivo metabolic stability, superior in vivo efficacy at low doses, low drug-drug interaction (DDI) risk, favorable safety profile, and low predicted human efficacious dose compared to leading available therapies or drug candidates in development.
"The nomination of ISM0676 (搜索) further enriches Insilico's cardiometabolic pipeline programs driven by generative AI exploration, which is currently one of the core strategies of the company," said Feng Ren, Ph.D., Co-CEO and Chief Scientific Officer of Insilico Medicine (搜索). "From highly novel mechanisms to well validated targets, from fibrosis and cancer to cardiometabolic diseases, Insilico has proved how AI can accelerate diversified areas."
Expanding Therapeutic Applications
ISM0676 (搜索) is designed for the treatment of obesity and associated diseases, including Type 2 diabetes, with broad potential expanding into obesity-associated cardiovascular diseases, such as heart failure. The compound represents part of Insilico's broader cardiometabolic strategy, which includes recent collaborations worth over $180 million in total deal value.
"Metabolism involves fundamental biological processes in human life and has long been considered one of the key aging hallmarks," said Alex Zhavoronkov, PhD., Founder and CEO, CBO of Insilico Medicine (搜索). "The nomination of ISM0676 (搜索) reflects how our Pharma.AI platform can rapidly design and optimize promising molecules to address urgent needs, bringing benefits for patients worldwide."
The nomination of ISM0676 (搜索) as a preclinical candidate marks a significant milestone in AI-driven drug discovery, demonstrating the potential for artificial intelligence to accelerate the development of novel therapeutics for metabolic diseases.